PrimerDesign

Primerdesign developed a COVID-19 diagnostic test and in March, 2020 announced that it had increased manufacturing capacity to support production of 2 million COVID-19 tests per month. Novacyt is seeking FDA, Emergency Use Approval (EUA). A favourable performance assessment by Public Health England (PHE) has been reported. The test is part of the Genesig product line and is a real time PCR (RT-PCR) test that is CE-IVD marked for in vitro diagnostics in EuropeEurope.

Primerdesign developed a COVID-19 diagnostic test and in March, 2020 announced that it had increased manufacturing capacity to support production of 2 million COVID-19 tests per month. Novacyt is seeking FDA, Emergency Use Approval (EUA). A favourable performance assessment by Public Health EnglandPublic Health England (PHE) has been reported. The test is part of the Genesig product line and is a real time PCR (RT-PCR) test that is CE-IVD marked for in vitro diagnostics in Europe.

Primerdesign designs, manufactures, validates and supplies real-time PCR kits and reagents. The company was founded in 2005 at Southampton University School of Medicine. Primerdesign became part of Novacyt Group in 2016.

Primerdesign developed a COVID-19 diagnostic test and in March, 2020 announced that it had increased manufacturing capacity to support production of 2 million COVID-19 tests per month. Novacyt is seeking FDA, Emergency Use Approval (EUA). A favourable performance assessment by Public Health England (PHE) has been reported. The test is part of the Genesig product line and is a real time PCR (RT-PCR) test that is CE-IVD marked for in vitro diagnostics in Europe.